Virax Biolabs Group Ltd (VRAX)

Every figure this model derived for VRAX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 603,890 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-03-31
cash 4,228,944 CashAndCashEquivalents 2025-03-31
current assets 4,893,655 CurrentAssets 2025-03-31
current liabilities 673,207 CurrentLiabilities 2025-03-31
equity 5,696,120 EquityAttributableToOwnersOfParent 2025-03-31
interest expense 78,953 InterestPaidClassifiedAsOperatingActivities 2025-03-31
ocf -4,563,576 CashFlowsFromUsedInOperatingActivities 2025-03-31
revenue 6,331 RevenueFromContractsWithCustomers 2025-03-31
sbc 365,309 AdjustmentsForSharebasedPayments 2025-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up VRAX on one particular measure came for.

RatioValue
current ratio7.27
current ratio reported7.27
dilution pct86.0
growth cv1.69
interest cover-78.06
revenue growth-95.95
revenue growth per share-97.82
roic-268.73
rule of 40-97440.72

What to be careful about

What this model itself distrusts about VRAX's figures. Written by the derivation as it ran, not added afterwards.